Skip to content
Screener

EyePoint, Inc. EYPT Other Income (Expense)

Other Income (Expense) at other companies

Merck & Co. logo
Merck & Co.MRK
-$99M-1,514%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$234.3M-46.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$4.73M+3,576%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$22K-320%
Regenxbio logo
RegenxbioRGNX
-$6.55M+13.7%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$4.86M-14.0%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Loss from operations(97,380)(62,227)(184,606)(111,064)
Other (expense) income:
Interest and other income, net2,9102,8945,2546,536
Total other income, net2,9102,8945,2546,536
Net loss before income taxes$(94,470)$(59,333)$(179,352)$(104,528)
Provision for income taxes(93)50(93)
Net loss$(94,470)$(59,426)$(179,302)$(104,621)
Net loss per share:

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s other income (expense)?
EyePoint, Inc. (EYPT) reported other income (expense) of $2.91M in Q2 2026.
How has EyePoint, Inc.'s other income (expense) changed year-over-year?
EyePoint, Inc.'s other income (expense) increased by 0.6% year-over-year, from $2.89M to $2.91M.
What is the long-term trend for EyePoint, Inc.'s other income (expense)?
Over 3 years (2021 to 2025), EyePoint, Inc.'s other income (expense) has grown at a 55.3% compound annual growth rate (CAGR), from -$3.14M to $11.75M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about EyePoint, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude